Alloy Therapeutics and Biogen enter collaboration to develop antisense therapeutics using the AntiClastic ASO platform, targeting intracellular RNA across multiple undisclosed programs.
Written By: Nikita Jha, BPharm
Reviewed By: Pharmacally Editorial Team
Alloy Therapeutics announced a collaboration and license agreement with Biogen Inc. to utilize Alloy’s proprietary AntiClastic™ antisense oligonucleotide (ASO) platform for the development of antisense therapeutics against multiple undisclosed targets. Under the agreement, Alloy will receive an upfront payment and is eligible for development and commercial milestone payments, along with tiered royalties on any resulting products.
Collaboration Focuses on RNA-Level Targeting
The agreement combines Biogen’s experience in developing innovative medicines with Alloy’s antisense discovery technologies. The AntiClastic ASO platform is designed to enable targeting of intracellular disease drivers at the RNA level. The technology aims to address longstanding limitations of antisense drugs, including restricted biodistribution, limited potency, and challenges with therapeutic index.
Alloy stated that the platform incorporates novel oligonucleotide formats intended to improve delivery to target RNA and enhance efficacy while reducing inflammatory responses. These design features are intended to expand the therapeutic potential of antisense approaches across multiple disease areas.
Leadership Commentary
Errik Anderson, CEO and Founder of Alloy Therapeutics, said the collaboration builds on an existing relationship with Biogen and provides access to Alloy’s AntiClastic platform and broader technology ecosystem. He emphasized that the partnership is intended to support the development of innovative therapies with potential clinical impact.
Jane Grogan, Executive Vice President and Head of Research at Biogen, noted that the collaboration aligns with Biogen’s strategy to explore novel scientific approaches for complex diseases. She added that partnering with Alloy expands Biogen’s research toolkit and supports advancement of programs aimed at benefiting patients globally.
AntiClastic ASO Platform Technology
The AntiClastic ASO platform, developed within Alloy’s Genetic Medicines division, introduces new oligonucleotide architectures designed to improve potency and therapeutic index. The core technology was invented by Sudhir Agrawal and combines optimized primary sequence design with a proprietary spatial conformation of nucleic acid drugs. This approach aims to enhance delivery to target RNA while mitigating inflammatory responses.
According to Alloy, candidates generated using the platform have demonstrated increased potency compared with traditional gapmer antisense formats. The technology can be applied either to existing antisense sequences or used to discover new AntiClastic oligonucleotide molecules for targeted therapeutic delivery.
Expanding Genetic Medicines Capabilities
Alloy said its broader drug discovery ecosystem integrates computational and AI-enabled approaches to support discovery and optimization of novel therapeutics. The collaboration with Biogen reflects continued efforts to expand access to advanced genetic medicine technologies and accelerate development of RNA-targeted treatments.
Reference
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform, 07 April 2026, https://alloytx.com/alloy-biogen-aso-platform-collaboration/
About the Writer
Nikita Jha BPharm is a pharmacy graduate with expertise in clinical research, pharmacovigilance, and medical writing. In her words, she is passionate about translating complex scientific data into clear, accurate healthcare communications that advance drug safety and patient care.